Advanced Research in Age-Related Macular Degeneration (AMD)
74,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

Age-related macular degeneration (AMD) is the main cause of irreversible vision loss in people over 60 years of age. Due to the aging of the global population in the coming decades, the number of patients with AMD is expected to increase significantly. The pathogenesis of AMD is based on a decrease in the metabolic and regenerative processes characteristic of aging and a violation of the microcirculation and structural organization of the retina, for which the prerequisites and mechanisms of the transition into the pathological process remain unclear. Therefore, studies on the molecular…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Age-related macular degeneration (AMD) is the main cause of irreversible vision loss in people over 60 years of age. Due to the aging of the global population in the coming decades, the number of patients with AMD is expected to increase significantly. The pathogenesis of AMD is based on a decrease in the metabolic and regenerative processes characteristic of aging and a violation of the microcirculation and structural organization of the retina, for which the prerequisites and mechanisms of the transition into the pathological process remain unclear. Therefore, studies on the molecular mechanisms of AMD pathogenesis and new approaches to its early diagnostics and treatments are urgently needed. In this Special Issue, authors were invited to contribute original clinical and experimental studies on different aspects related to the theme of "Advanced Research in AMD". Through these published articles, this Issue provided new insights into the diagnosis and treatment of AMD and has the potential to impact current and future knowledge regarding the pathogenesis and treatment of patients with AMD. New diagnostic approaches and treatment regimens, the development of multimodal visualization methods and the potential genetic and OCT markers of treatment response may help guide the future management of this disease.